Search

Displaying results 2431 - 2440 of 4190 in total
  1. Drug

    Nesbuvir

    go.drugbank.com/drugs/DB07238
    Investigational

    Nesbuvir has been investigated for the treatment of Hepatitis C.

  2. Drug

    Emodin

    go.drugbank.com/drugs/DB07715
    Investigational

    Emodin has been investigated for the treatment of Polycystic Kidney.

  3. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevent...

  4. Drug

    Tazobactam

    go.drugbank.com/drugs/DB01606
    ApprovedInvestigational

    Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a vari...

  5. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits protein expression in cell cul...

  6. Drug

    Evening primrose oil

    go.drugbank.com/drugs/DB11358
    ApprovedNutraceutical

    [A33131] Evening primrose oil has been filled for the FDA by Humanetics Corporation on April 2000 to be a new dietary ingredient but its current status is "Inadequate basis for expectation of safety".

  7. Drug

    Atezolizumab

    go.drugbank.com/drugs/DB11595
    ApprovedInvestigational

    Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.

  8. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    [T210] Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine.

  9. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct

  10. Drug

    Zidovudine

    go.drugbank.com/drugs/DB00495
    ApprovedInvestigational

    A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group.